High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial

被引:35
作者
Johnson, Kara [1 ,2 ]
McEvoy, Charlene E. [3 ]
Naqvi, Sakina [1 ,4 ]
Wendt, Chris [1 ]
Reilkoff, Ronald A. [4 ,5 ]
Kunisaki, Ken M. [1 ]
Wetherbee, Erin E. [1 ]
Nelson, David [6 ]
Tirouvanziam, Rabindra [7 ]
Niewoehner, Dennis E. [1 ]
机构
[1] Minneapolis VA Hlth Care Syst, Pulm Sect, 111N,1 Vet Dr, Minneapolis, MN 55417 USA
[2] Sanford Hlth, Fargo, ND USA
[3] HealthPartners Res Fdn, Pulm Sect, St Paul, MN USA
[4] HealthEast Maplewood Clin, Maplewood, MN USA
[5] Univ Minnesota, Med Ctr, Pulm Sect, Minneapolis, MN 55455 USA
[6] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA
[7] Emory Univ, Sch Med, Ctr Cyst Fibrosis & Airways Dis Res, Atlanta, GA USA
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2016年 / 11卷
关键词
COPD; chronic bronchitis; N-acetylcysteine; BRONCHOALVEOLAR LAVAGE FLUID; GLUTATHIONE; CYSTEINE; OUTCOMES; PLASMA; COPD;
D O I
10.2147/COPD.S102375
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Clinical outcomes are worse in patients with COPD and chronic bronchitis. N-acetylcysteine (NAC) is commonly prescribed for such patients but with uncertain clinical benefits. We postulated that oral NAC, at much larger doses than those ordinarily prescribed, would improve clinical outcomes in a subset of patients with COPD and chronic bronchitis. Objective: The aim of this study was to determine whether very high-dose NAC would improve respiratory health status in patients with COPD and chronic bronchitis. Methods: Patients with COPD and chronic bronchitis were enrolled in a randomized, controlled, double-blinded trial. Patients received oral NAC (1,800 mg) or matching placebo twice daily for 8 weeks in addition to their usual respiratory medications. The primary outcome, respiratory health status, was assessed by changes in the St George's Respiratory Questionnaire. The effects of NAC on lung function and circulating markers of oxidative stress and inflammation were also evaluated. Results: We terminated the study prematurely because new external information suggested the possibility of a safety issue. Of the planned 130 patients, 51 were randomized and 45 (22 in the placebo arm and 23 in the NAC arm) completed the study. There was no statistically significant difference between changes in the St George's Respiratory Questionnaire total score, comparing NAC to placebo (adjusted mean difference, 0.1 U; 95% CI, -7.8 to 8.18 U; P=0.97). There were also no significant NAC-related improvements in any of the secondary outcomes. Conclusion: In this 8-week trial, we were unable to show any clinical benefit from a very high dose of NAC in patients with COPD and chronic bronchitis.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 34 条
[1]   Plasma 8-isoprostane is increased in preterm infants who develop bronchopulmonary dysplasia or periventricular leukomalacia [J].
Ahola, T ;
Fellman, V ;
Kjellmer, I ;
Raivio, KO ;
Lapatto, R .
PEDIATRIC RESEARCH, 2004, 56 (01) :88-93
[2]  
[Anonymous], CHRON OBSTR PULM DIS
[3]   N-Acetylcysteine -: a safe antidote for cysteine/glutathione deficiency [J].
Atkuri, Kondala R. ;
Mantovani, John J. ;
Herzenberg, Leonard A. ;
Herzenberg, Leonore A. .
CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (04) :355-359
[4]  
Au David H, 2005, COPD, V2, P209
[5]   Supplemental vitamin D and physical performance in COPD: a pilot randomized trial [J].
Bjerk, Sonja M. ;
Edgington, Bradley D. ;
Rector, Thomas S. ;
Kunisaki, Ken M. .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2013, 8 :97-104
[6]   PREVENTIVE ADMINISTRATION OF INTRAVENOUS N-ACETYLCYSTEINE AND DEVELOPMENT OF TOLERANCE TO ISOSORBIDE DINITRATE IN PATIENTS WITH ANGINA-PECTORIS [J].
BOESGAARD, S ;
ALDERSHVILE, J ;
POULSEN, HE .
CIRCULATION, 1992, 85 (01) :143-149
[7]   EFFECT OF N-ACETYL CYSTEINE ON THE CONCENTRATIONS OF THIOLS IN PLASMA, BRONCHOALVEOLAR LAVAGE FLUID, AND LUNG-TISSUE [J].
BRIDGEMAN, MME ;
MARSDEN, M ;
SELBY, C ;
MORRISON, D ;
MACNEE, W .
THORAX, 1994, 49 (07) :670-675
[8]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[9]   NORMAL ALVEOLAR EPITHELIAL LINING FLUID CONTAINS HIGH-LEVELS OF GLUTATHIONE [J].
CANTIN, AM ;
NORTH, SL ;
HUBBARD, RC ;
CRYSTAL, RG .
JOURNAL OF APPLIED PHYSIOLOGY, 1987, 63 (01) :152-157
[10]  
Cotgreave I A, 1997, Adv Pharmacol, V38, P205